{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:13Z","timestamp":1753891813179,"version":"3.41.2"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The prognosis of patients with peripheral T-cell (PTCL) or lymphoblastic T-cell lymphoma (T-LBL) remains poor under current conditioning regimens before receiving autologous stem cell transplantation (ASCT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with PTCL or T-LBL were enrolled to receive ASCT using the conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan (ChiCGB). Positron emission tomography-computed tomography (PET\/CT) was used to evaluate the response to ASCT. Overall survival (OS) and progression-free survival (PFS) were employed to assess the patient outcome, and adverse events were used to assess the regimen\u2019s safety. The survival curve was estimated <jats:italic>via<\/jats:italic> the Kaplan-Meier method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-five PTCL and 11 T-LBL patients were recruited. The median time to neutrophile and platelet engraftments was 10 days (8\u201313 days) and 13 days (9\u201331 days), respectively. The 3-year PFS and OS were 81.3 \u00b1 7.2% and 88.5 \u00b1 5.4% for all patients; 92.0 \u00b1 5.4% and 81.2 \u00b1 8.8% for PTCL patients; and both 81.8 \u00b1 11.6% for T-LBL patients, respectively. The 3-year PFS and OS were both 92.9 \u00b1 4.9% for patients with complete response (CR) but 50.0 \u00b1 17.7% and 75.0 \u00b1 15.3% for patients with non-CR, respectively. Infection was the most common non-hematological toxicity, and all toxicities were mild and controllable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ChiCGB was a potentially effective and well-tolerated conditioning regimen to improve the prognosis of patients with aggressive T-cell lymphoma. Future randomized controlled trials are needed to assess ChiCGB as a conditioning regimen for ASCT.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1143556","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T05:59:15Z","timestamp":1678341555000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Qiang","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pu","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinchuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"623924","DOI":"10.5402\/2011\/623924","article-title":"A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma","volume":"2011","author":"Abouyabis","year":"2011","journal-title":"ISRN Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single north American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01310-3","article-title":"Management of peripheral T-cell lymphomas and the role of transplant","volume":"24","author":"Foley","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279426","article-title":"Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study","volume":"107","author":"Garc\u00eda-Sancho","year":"2022","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.01.032","article-title":"BEAM versus BUCYVP16 conditioning before autologous hematopoietic stem cell transplant in patients with Hodgkin lymphoma","volume":"25","author":"Singer","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.003","article-title":"Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural Killer\/T cell lymphoma","volume":"21","author":"Yhim","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1037764","article-title":"High-dose therapy and autologous stem cell transplantation for extra-nodal NK\/T lymphoma in patients from the Western hemisphere: A study from the European society for blood and marrow transplantation","volume":"56","author":"Fox","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0463-y","article-title":"BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-hodgkin's lymphomas","volume":"54","author":"Singer","year":"2019","journal-title":"Bone Marrow Transpl"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2016.03.001","article-title":"Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study","volume":"44","author":"Ji","year":"2016","journal-title":"Exp Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33761","article-title":"A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed\/refractory non-hodgkin's lymphomas","volume":"149","author":"Ji","year":"2021","journal-title":"Int J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1563691","article-title":"Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis","volume":"60","author":"Al-Mansour","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1185785","article-title":"Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed\/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: Alternatives to BEAM conditioning","volume":"57","author":"Isidori","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.02.005","article-title":"Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the gel-tamo study group","volume":"79","author":"Rodr\u00edguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/hon.64_2629","article-title":"First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidation-final results of the AATT study","volume":"17","author":"Tournilhac","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.23067","article-title":"Outcome and prospective factor analysis of high-dose therapy combined with autologous peripheral blood stem cell transplantation in patients with peripheral T-cell lymphomas","volume":"15","author":"Wu","year":"2018","journal-title":"Int J Med Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl466","article-title":"The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: The Spanish lymphoma and autologous transplantation group experience","volume":"18","author":"Rodr\u00edguez","year":"2007","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3760\/cma.j.issn.0253-2727.2020.03.003","article-title":"[Autologous hematopoietic stem cell transplantation treatment for T cell lymphoblastic lymphoma]","volume":"41","author":"Wang","year":"2020","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl426","article-title":"Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes","volume":"18","author":"Song","year":"2007","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.226985","article-title":"Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China","volume":"106","author":"Liu","year":"2021","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: An analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.07.005","article-title":"A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission","volume":"13","author":"Mehta","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.165","article-title":"Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group","volume":"45","author":"Numata","year":"2010","journal-title":"Bone Marrow Transpl"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study","volume":"40","author":"Feyler","year":"2007","journal-title":"Bone Marrow Transpl"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh471","article-title":"All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: A matched-control analysis by the groupe d'Etude des lymphomes de l'Adulte (GELA)","volume":"15","author":"Mounier","year":"2004","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.05.009","article-title":"A comparison of the BEAM and MITO\/MEL conditioning regimens for autologous hematopoietic stem cell transplantation in Hodgkin lymphoma: An analysis of efficiency and treatment-related toxicity","volume":"20","author":"Yeral","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004167","article-title":"Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma","volume":"5","author":"Dahi","year":"2021","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0360-0","article-title":"BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity","volume":"87","author":"Jo","year":"2008","journal-title":"Ann Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702795","article-title":"Autologous stem cell transplantation for clinically aggressive non-hodgkin's lymphoma: the role of preparative regimens","volume":"27","author":"Salar","year":"2001","journal-title":"Bone Marrow Transpl"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701593628","article-title":"Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large b-cell lymphoma with unusual clinical and pathologic findings","volume":"48","author":"Maegawa","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"B34","article-title":"Diffuse large b-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Skugor","year":"2010","journal-title":"Coll Antropol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1309\/6UTX-GVC0-12ND-JJEU","article-title":"Epstein-Barr Virus-associated b-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified","volume":"117","author":"Zettl","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.2153034.x","article-title":"Epstein-Barr Virus associated b-cell lymphoma after autologous bone marrow transplantation for T-cell acute lymphoblastic leukaemia","volume":"98","author":"Briz","year":"1997","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1143556\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T05:59:18Z","timestamp":1678341558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1143556\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":36,"alternative-id":["10.3389\/fonc.2023.1143556"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1143556","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"article-number":"1143556"}}